Botulinum toxin is a potent inhibitor ofthe release of acetylcholine from nerve endings. It has previously been shown that it can effectively reduce lower oesophageal sphincter pressures both in animals and humans with achalasia. This study examined the hypothesis that locally injected botulinum toxin could also reduce sphincter of Oddi pressure in patients with sphincter of Oddi dysfunction. Two intravenously. Both static and dynamic images were obtained for the next 60 minutes. Counts were obtained from two regions of interest: the right lobe of the liver and the common bile duct. As previously described, a numeric score (range 0 to 12) was assigned to each scan, based on several parameters.4 According to this system, a score of 5 or more denotes sphincter of Oddi dysfunction, 'normal' scores being 0-4. In a prospective blinded study, the degree of correlation between this scintigraphic score and manometrically defined sphincter of Oddi dysfunction was shown to be 100%.4
examined the hypothesis that locally injected botulinum toxin could also reduce sphincter of Oddi pressure in patients with sphincter of Oddi dysfunction. Two patients with postcholecystectomy pain syndrome were diagnosed with sphincter ofOddi dysfunction (by biliary manometry in one patient and by hepatobiliary scanning criteria in the other). Botulinum toxin was injected into the sphincter of Oddi, by a sclerotherapy needle passed through a duodenoscope. In the first patient, intrasphincteric injection of botulinum toxin reduced sphincter pressure by about 50%, an effect that was sustained for at least four months. In the second patient, intrasphincteric injection caused about a 50% improvement in bile flow, with normalisation of scintigraph'y. Neither patient showed any sustained improvement in pain despite these objective findings. Both (Fig 2) . Scintigraphic criteria to the normalised with a score of 1. There was no Llidated clinical improvement, however, in response in this to either the injection or a subsequent Low any sphincterotomy. No side effects were seen. showed 57 mm f a pro-Discussion arative Recurrent postcholecystectomy pain is a common clinical problem, affecting 10% or more patients undergoing cholecystectomy every year.5 6 Sphincter of Oddi dysfunction has been implicated in the aetiology of 10-20% of these cases.5 Such dysfunction can result from a true stenosis or secondary to spasm of the sphincter. In most cases, sphincter of Oddi dysfunction continues to present problems, both in terms of diagnosis as well as treatment. Although muscle spasm is thought to play a significant part in these cases, the response to conventional smooth muscle relaxants such as '~~'.--nitrates and calcium channel antagonists has $8.0 60.0 been disappointing.' 7 8 Sphincterotomy is considered to be the most effective treatment for patients with sphincter aetientare of Oddi dysfunction. This effect ofbotulinum toxin has the potential for being clinically useful in two ways. Firstly, intrasphincteric injection of botulinum toxin (followed by scintigraphic improvement in bile flow) may serve as a useful and simple therapeutic trial to select patients whose pain is caused by sphincter of Oddi dysfunction. Sphincterotomy may therefore be avoided in those patients whose pain does not respond to botulinum toxin injection (such as the two patients in this report). Secondly, if longterm efficacy is established, botulinum toxin may prove to be a viable and potentially safer therapeutic alternative to sphincterotomy in patients whose pain is truly secondary to sphincter dysfunction. The validity of both these attractive hypotheses needs to be tested by further prospective studies, which are being carrlied out at our institution. 
